RECCE PHARMACEUTICALS LTD — Capital/Financing Update 2019

Jan 15, 2019

ASX Announcement

Funding Update

Sydney, Australia, 16 January 2019: Further to the Funding Update announcement made to the market on 18 December 2018 by Recce Pharmaceuticals Ltd (ASX: RCE) ( Company ), regarding a short term loan provided by a director of the Company, the Company wishes to provide the following update.

The Company is currently reviewing a number of potential funding options to support the Company’s future capital requirements. At this stage, the Company has not entered into or approved any funding arrangement which has not previously been announced to the market.

As soon as the Company has finalised any funding arrangement and is in a position to announce such an arrangement, it will update the market accordingly.

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs. Its patented lead candidate known as RECCE[®] 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms. Pre-clinical testing in laboratories and animal models, in Australia and overseas has demonstrated positive results. Recce has a manufacturing facility in Australia and is developing clinical research partners in the USA. The Company has developed an automated process to manufacture its lead compound ahead of first-in-human clinical trials.

==> picture [595 x 99] intentionally omitted <==